Dr. Ashwin Kishtagari, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 15
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 114
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
TN license 63376 -
Internal Medicine Physician
TN license 63376 -
Medical Oncology Physician
TN license 63376 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Vanderbilt University Medical Center Nashville, TN
Medical groups
- Vanderbilt Health Clinicians, LLC (129 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 114
- Services billed
- 367
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 212 | 89 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 103 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 71 | 21 |
| Established patient office or other outpatient visit, 40-54 minutes | 48 | 34 |
| New patient office or other outpatient visit, 60-74 minutes | 42 | 42 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 28 | 28 |
| Hospital discharge day management, more than 30 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Vonjo (pacritinib citrate) | 40 |
| Jakafi (ruxolitinib phosphate) | 32 |
| Ayvakit (avapritinib) | 23 |
| Hydroxyurea Other prescribers in Nashville, TN | 17 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Nashville, TN | 14 |
| Venclexta (venetoclax) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 30 payments worth $22,880 in total to this clinician.
| Sobi, Inc | $7,644 |
|---|---|
| Geron Corporation | $5,744 |
| Syndax Pharmaceuticals, Inc. | $2,393 |
| Novartis Pharmaceuticals Corporation | $2,248 |
| Blueprint Medicines Corporation | $2,184 |
| Siemens Medical Solutions USA, Inc. | $1,035 |
| Takeda Pharmaceuticals U.S.A., Inc. | $850 |
| Daiichi Sankyo Inc. | $650 |
| Consulting Fee | $12,133 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,150 |
| Honoraria | $2,041 |
| Travel and Lodging | $1,599 |
| Food and Beverage | $958 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Sobi, Inc Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) Vonjo · Hematology/Oncology | $5,115 |
| Geron Corporation Oct 28, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $4,260 |
| Syndax Pharmaceuticals, Inc. Aug 7, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,385 |
| Novartis Pharmaceuticals Corporation Aug 27, 2025 | Consulting Fee Fabhalta · Immunology | $2,063 |
| Blueprint Medicines Corporation Mar 5, 2025 | Honoraria | $2,041 |
| Sobi, Inc Nov 25, 2025 | Consulting Fee Vonjo · Hematology/Oncology | $1,925 |
| Siemens Medical Solutions USA, Inc. Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,035 |
| Geron Corporation Oct 28, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to DALLAS, TX | $959 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 17, 2025 | Consulting Fee | $850 |
| Daiichi Sankyo Inc. Sep 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
All 15 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Sobi, Inc Nov 25, 2025 | Consulting Fee Vonjo · Hematology/Oncology | $1,925 |
| Geron Corporation Oct 28, 2025 | Consulting Fee IMETELSTAT · HEMATOLOGY | $4,260 |
| Geron Corporation Oct 28, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to DALLAS, TX | $959 |
| Geron Corporation Oct 28, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to DALLAS, TX | $130 |
| Geron Corporation Oct 28, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to DALLAS, TX | $39.36 |
| Geron Corporation Oct 25, 2025 | Travel and Lodging IMETELSTAT · HEMATOLOGY · travel to DALLAS, TX | $219 |
| Siemens Medical Solutions USA, Inc. Sep 26, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,035 |
| Daiichi Sankyo Inc. Sep 22, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $650 |
| Novartis Pharmaceuticals Corporation Aug 27, 2025 | Consulting Fee Fabhalta · Immunology | $2,063 |
| Sobi, Inc Aug 22, 2025 | Compensation for services other than consulting (speaking, faculty) Vonjo · Hematology/Oncology | $5,115 |
| Syndax Pharmaceuticals, Inc. Aug 7, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $2,385 |
| Takeda Pharmaceuticals U.S.A., Inc. Jul 17, 2025 | Consulting Fee | $850 |
| Sobi, Inc May 22, 2025 | Travel and Lodging Vonjo · Hematology/Oncology · travel to Detroit, MI | $238 |
| Blueprint Medicines Corporation Mar 5, 2025 | Honoraria | $2,041 |
| Blueprint Medicines Corporation Mar 5, 2025 | Travel and Lodging travel to Nashville, TN · in-kind | $13.71 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $255,185 in research payments for these studies, mostly to the institutions running them.
- A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Takeda Pharmaceuticals U.S.A., Inc. - A Phase 1b, Open Label, Multi-center, Dose Optimization and Dose Expansion Study to Assess the Safety and Efficacy of DFV890 in Adult Patients With Myeloid Diseases
Novartis Pharmaceuticals Corporation - A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Sumitomo Pharma America, Inc. · Recruiting · NCT04176198 - A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation - This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.